That’s what Sigma-Aldrich
/quotes/zigman/77951/delayed/quotes/zigman/77951/lastsaleSIAL paid in domestic income taxes last year on the $657 million it reported in pretax income for 2013. It amounts to just under 20% of the St. Louis-based company’s income, and presumably that figure will be dropping once the company’s headquarters is relocated to Germany.

Further, the tax bill for Sigma-Aldrich actually will end up being higher than it is now, reports say. It’s effective tax rate now is roughly 25% to 26% when money made on foreign sales is included. In Germany, that’s expected to jump to just under 30%, reports said.

But the U.S. won’t reap the rewards of roughly $130 million in taxes once the deal is complete. Merck said Monday it is paying $140 a share for Sigma-Aldrich, more than a third higher than the $102.37 closing price for Sigma-Aldrich on Friday.

Shares of Sigma-Aldrich jumped more than 33% to $136.40 on the deal, while Merck added more than 4% to 72.63 euros ($93.30). Merck’s life-science operations gets a boost from the deal, as revenue from that part of the business is expected to double. Sigma-Aldrich’s 2013 revenue was $2.7 billion.

Story Conversation

About Health Exchange

Health Exchange guides investors to the crucial market intelligence they need to keep up with the health care industry, which makes up one-sixth of the U.S. economy. Anchored by Russ Britt, Health Exchange is the essential site for those looking for the most important news, data and analysis on the sector. You can reach Russ at Rbritt@marketwatch.com.